Karyopharm Therapeutics | KPTI - Pre Tax Profit


Karyopharm Therapeutics reported $-39.9M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Abbott USD 2.39B 27M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Incyte USD 343.6M 46.34M Mar/2026
J&J USD 7.82B 2.86B Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Novartis USD 3.84B 802M Mar/2026
Novartis USD 5.17B 637M Sep/2025
Pfizer USD 5.18B 6.82B Mar/2026
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Takeda JPY -52.48B 186.34B Mar/2026
Tectonic Therapeutic USD -18.97M 63K Dec/2025
TG Therapeutics USD 20.36M 24.73M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Xencor USD -128.64M 124.37M Mar/2026